来自Hemiscorpius lepturus的重组脂酶A2的生物化学表征和活性概况,表达在E. coli中,具有体内抗体反应
Moslem Najafi1,2, Delavar Shahbazzadeh2, Parichehreh Yaghmaie1
1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Scientific reports
|April 26, 2025
概括
研究人员从伊朗子毒中鉴定了脂酶A2 (PLA2),发现它具有抗菌和致命的特性. 这种酶显示出潜在的药物或疫苗候选人对子中毒.
科学领域:
- 生物化学 生物化学
- 毒理学 毒理学 毒理学
- 免疫学 免疫学 免疫学
背景情况:
- 在子毒中脂酶A2 (PLA2) 的结构和功能在很大程度上仍未被描述.
- 了解子毒的成分对于开发有效的抗毒药和治疗方法至关重要.
研究的目的:
- 从生物化学上识别和表征来自伊朗黑鱼 (Hemiscorpius lepturus) 毒的PLA2.
- 研究针对PLA2的多克隆抗体的体内疗效.
- 探索PLA2作为治疗治疗子中毒的治疗剂的潜力.
主要方法:
- 在大肠杆菌中克隆和表达PLA2基因,然后使用亲和染色法进行净化.
- 通过CD光谱学分析复合PLA2的二次结构.
- 生物化学测试以确定脂酶活性,最佳温度和pH值,最小抑制度 (MIC) 和最小杀菌度 (MBC).
- 给子免疫,以产生针对PLA2的多克隆抗体,并通过ELISA检测.
主要成果:
- 磁盘光谱学揭示了一个独特的二次结构:45.1%的β-sheet,36.6%的随机线圈,10.3%的转向和8.1%的α-helix.
- 在25°C时观察到最佳的PLA2活性,在37°C时保持显著活性.
- 在度分别为31.25微克/毫升和0.5毫克/毫升时,MIC和MBC值表明强烈的抗菌和致命性质.
结论:
- 来自H. lepturus的特征PLA2酶表现出显著的酶活性,并具有抗菌和致命的特性.
- 生成的多克隆抗体显示出对诊断或治疗应用的前景.
- 这种PLA2酶是未来针对H. lepturus中毒的药物或疫苗开发的潜在候选者.
更多相关视频
08:46Cell-Free Production of Proteoliposomes for Functional Analysis and Antibody Development Targeting Membrane Proteins
Published on: September 22, 2020
3.7K
12:12Identification of Hemolytic and Phospholipase Activity in Crude Extracts from Sea Anemones by Straightforward Bioassays
Published on: March 29, 2022
2.7K
相关概念视频
01:23Stringent Response in E. coli
Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...